Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biotricity, Inc. (BTCY)
USD0.11
+0.01 (+9.95%)
US OTC Healthcare Medical - Devices
Address
275 Shoreline Drive 94065
Redwood City, CA, US
Redwood City, CA, US
CEO
Waqaas Al-Siddiq
Website
biotricity.com
IPO
2018-02-16
CIK 1630113 ISIN US09074H2031
Description
Headquartered in Redwood City, California, Biotricity, Inc. is a medical technology enterprise delivering biometric data monitoring solutions, primarily within the United States. The company's efforts are dedicated to supplying remote monitoring capabilities to the medical, healthcare, and individual consumer markets, encompassing both diagnostic tools and ongoing management support for chronic and lifestyle-related conditions. Among its key offerings are the Bioflux mobile cardiac telemetry solution, an integrated ECG device, alongside specialized ECG analysis software designed to process and synthesize patient heart rhythm data, complemented by various software components.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.11
+0.01 (+9.95%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
67.8K
Beta
1.15
Float Shares
16.56M
Free Float %
58.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +7.38% | -44.26% | -49.86% | -72.71% | -56.33% | -76.18% | -96.88% | -99.24% | -98.91% | -99.18% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
0.11
Low
4.00
+3,567.7%
Consensus
4.00
+3,567.7%
Median
4.00
+3,567.7%
High
4.00
+3,567.7%
Ratings Trend (MoM)
0% Bullish
| Rating | 2025-10 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
4.00
+3,567.7%
|
Quality scores
Altman Z-Score
-36.15
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+14.3% ★ Q4'25: +10.2% (vs Q4'24)
-
EPS growth Medical - Devices: +28.5%+66.9% ★ Q4'25: +23.5% (vs Q4'24)
-
FCF margin FCF growth · Medical - Devices: +30.9%-54.1% Q4'25: -18.6% (vs Q4'24)
-
EBIT margin Medical - Devices: +6.2%-23.3% Q4'25: +11.1% (vs Q4'24)
-
ROIC Medical - Devices: +3.3%— Q4'25: -31.0% (vs Q4'24)
-
Share dilution Medical - Devices: 0.0%+139.4% Q4'25: +13.9% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-8.12× Q4'25: 15.36× (vs Q4'24)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
7.65M
est: 7.61M (+0.6%)
|
9.64M
est: 9.50M (+1.5%)
|
12.06M
est: 12.24M (-1.5%)
|
13.79M
est: 13.70M (+0.7%)
|
15.80M
15.80M – 15.80M
+15.3% YoY
|
| EBITDA |
-18.56M
est: -6.04M (-207.2%)
|
-16.07M
est: -7.54M (-113.0%)
|
-8.90M
est: -9.72M (+8.5%)
|
-3.21M
est: -10.88M (+70.5%)
|
-12.55M
-12.55M – -12.55M
-15.3% YoY
|
| EBIT |
-18.56M
est: -6.04M (-207.2%)
|
-16.08M
est: -7.55M (-113.0%)
|
-8.90M
est: -9.73M (+8.5%)
|
-3.22M
est: -10.88M (+70.4%)
|
-12.55M
-12.55M – -12.55M
-15.3% YoY
|
| Net Income |
-29.13M
est: -74.58M (+60.9%)
|
-18.66M
est: -49.08M (+62.0%)
|
-14.09M
|
-8.42M
est: -12.48M (+32.5%)
|
-6.89M
-6.89M – -6.89M
+44.8% YoY
|
| SGA |
18.56M
est: 15.16M (+22.4%)
|
17.62M
est: 18.93M (-6.9%)
|
14.61M
est: 24.40M (-40.1%)
|
10.86M
est: 27.31M (-60.2%)
|
31.49M
31.49M – 31.49M
+15.3% YoY
|
| EPS |
-3.99
est: -3.47 (-15.2%)
|
-2.26
est: -2.28 (+0.9%)
|
-1.66
|
-0.55
est: -0.58 (+5.2%)
|
-0.32
-0.32 – -0.32
+44.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-860.8K
OE per share TTM
-0.03
Owner's Yield
-23.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
10.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
2
Total invested
15.7K
Insider transactions (90d)
0
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Brendan O’Neil | 2.42M | 9.90% | — | 2.42M | — | 2.42M | IN | California, United States | 2024-08-08 | ↗ |
| 2 | Ionic Ventures, LLC | 2.42M | 9.90% | — | 2.42M | — | 2.42M | OO | California, United States | 2024-08-08 | ↗ |
| 3 | Keith Coulston | 2.42M | 9.90% | — | 2.42M | — | 2.42M | IN | California, United States | 2024-08-08 | ↗ |
| 4 | Management, LLC | 2.42M | 9.90% | — | 2.42M | — | 2.42M | OO | California, United States | 2024-08-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
2
+1 vs prev Q
New positions
1
Closed positions
0
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | STRENGTHENING FAMILIES & COMMUNITIES, LLC | 48.3K +48.3K (+100.0%) | 11.4K +11.4K (+100.0%) | 0.17% +0.175 pp | 0.00% +0.003 pp | USD0.24 +0.0% | 3 qtrs — |
| 2 | — | 18.3K +— (+0.0%) | 4.3K -1.2K (-21.3%) | 0.07% +0.000 pp | 0.00% -0.001 pp | USD0.30 -20.0% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
1.78M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,775,930
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-12 | Rosa David A | Director | A-Award | A | Option (right to buy) | 75,930 | 1.94 | 147.3K | 474,683 | — | ↗ |
| 2023-03-12 | Al-Siddiq Waqaas | Director / Officer | A-Award | A | Option (right to purchase) | 1,000,000 | 0.81 | 810.0K | 4,899,984 | — | ↗ |
| 2022-12-31 | Ayanoglou John | Officer | A-Award | A | Warrants | 218,785 | 0.45 | 98.0K | 1,328,488 | — | ↗ |
| 2022-09-30 | Ayanoglou John | Officer | A-Award | A | Warrants | 118,282 | 0.80 | 94.6K | 1,109,703 | — | ↗ |
| 2022-06-30 | Ayanoglou John | Officer | A-Award | A | Warrants | 53,827 | 1.77 | 95.3K | 991,421 | — | ↗ |
| 2022-03-31 | Ayanoglou John | Officer | A-Award | A | Warrants | 37,594 | 2.27 | 85.3K | 937,594 | — | ↗ |
| 2021-12-31 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 2.40 | 120.0K | 900,000 | — | ↗ |
| 2021-11-29 | Rosa David A | Director | A-Award | A | Common Stock | 27,174 | 0.00 | — | 152,174 | — | ↗ |
| 2021-11-29 | Betts Norman M. | Director | A-Award | A | Common Stock | 54,348 | 0.00 | — | 375,598 | — | ↗ |
| 2021-10-11 | Rosa David A | Director | S-Sale | D | Common Stock | 3,318 | 3.05 | 10.1K | 125,000 | — | ↗ |
| 2021-10-08 | Rosa David A | Director | S-Sale | D | Common Stock | 9,481 | 3.20 | 30.3K | 128,318 | — | ↗ |
| 2021-10-07 | Rosa David A | Director | S-Sale | D | Common Stock | 17,228 | 3.08 | 53.1K | 137,799 | — | ↗ |
| 2021-09-30 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 2.40 | 120.0K | 850,000 | — | ↗ |
| 2021-09-16 | Rosa David A | Director | S-Sale | D | Common Stock | 34,977 | 3.43 | 119.9K | 155,027 | — | ↗ |
| 2021-09-15 | Rosa David A | Director | S-Sale | D | Common Stock | 6,246 | 3.27 | 20.4K | 190,004 | — | ↗ |
| 2021-06-30 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 2.40 | 120.0K | 800,000 | — | ↗ |
| 2021-03-31 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 2.40 | 120.0K | 750,000 | — | ↗ |
| 2021-03-21 | Rosa David A | Director | A-Award | A | Option (right to buy) | 31,106 | 2.40 | 74.7K | 398,753 | — | ↗ |
| 2020-12-31 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.74 | 37.0K | 700,000 | — | ↗ |
| 2020-09-30 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 1.11 | 55.5K | 600,000 | — | ↗ |
| 2020-06-30 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 1.37 | 68.4K | 550,000 | — | ↗ |
| 2020-04-23 | Salmon Stephen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-04-07 | Rosa David A | Director | A-Award | A | Option (right to purchase) | 367,647 | 0.98 | 360.3K | 367,647 | — | ↗ |
| 2020-04-07 | Kennedy Patricia J | Director | A-Award | A | Common Stock | 125,000 | 0.00 | — | 250,000 | — | ↗ |
| 2020-04-07 | Betts Norman M. | Director | A-Award | A | Common Stock | 125,000 | 0.00 | — | 321,250 | — | ↗ |
| 2020-04-07 | Al-Siddiq Waqaas | Officer | A-Award | A | Option (right to purchase) | 1,400,000 | 0.00 | — | 1,400,000 | — | ↗ |
| 2020-03-31 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.97 | 48.7K | 500,000 | — | ↗ |
| 2020-01-24 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.75 | 37.5K | 650,000 | — | ↗ |
| 2019-12-31 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.63 | 31.5K | 450,000 | — | ↗ |
| 2019-09-30 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.58 | 29.0K | 400,000 | — | ↗ |
| 2019-07-16 | Rosa David A | Director | — | D | Common Stock | 0 | 0.00 | — | 196,250 | — | ↗ |
| 2019-07-16 | Kennedy Patricia J | Director | — | D | Common Stock | 0 | 0.00 | — | 125,000 | — | ↗ |
| 2019-07-16 | Betts Norman M. | Director | — | D | Common Stock | 0 | 0.00 | — | 196,250 | — | ↗ |
| 2019-07-16 | Ayanoglou John | Officer | — | D | Common Stock | 0 | 0.00 | — | 41,667 | — | ↗ |
| 2019-07-16 | Al-Siddiq Waqaas | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,712,336 | — | ↗ |
| 2019-06-30 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.66 | 33.0K | 350,000 | — | ↗ |
| 2019-03-31 | Rosa David A | Director | — | D | Options (Right to buy) | 31,250 | 2.00 | 62.5K | 0 | — | ↗ |
| 2019-03-31 | Kennedy Patricia J | Director | — | D | Options (Right to buy) | 13,021 | 2.00 | 26.0K | 0 | — | ↗ |
| 2019-03-31 | Betts Norman M. | Director | — | D | Options (Right to buy) | 31,250 | 2.00 | 62.5K | 0 | — | ↗ |
| 2019-03-31 | Ayanoglou John | Officer | — | D | Warrants (Right to buy) | 50,000 | 0.91 | 45.5K | 0 | — | ↗ |
| 2018-12-31 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.48 | 24.0K | 250,000 | — | ↗ |
| 2018-09-30 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.73 | 36.5K | 200,000 | — | ↗ |
| 2018-06-30 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.73 | 36.5K | 150,000 | — | ↗ |
| 2018-03-31 | Rosa David A | Director | — | D | Warrants (Right to buy) | 20,000 | 2.00 | 40.0K | 0 | — | ↗ |
| 2018-03-31 | Betts Norman M. | Director | — | D | Warrants (Right to buy) | 20,000 | 2.00 | 40.0K | 0 | — | ↗ |
| 2018-03-31 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.73 | 36.5K | 100,000 | — | ↗ |
| 2017-12-05 | Ayanoglou John | Officer | — | I | Warrants (Right to Buy) | 13,806 | 3.50 | 48.3K | 0 | — | ↗ |
| 2017-10-26 | Ayanoglou John | Officer | A-Award | A | Warrants | 50,000 | 0.73 | 36.5K | 50,000 | — | ↗ |
| 2017-09-30 | Ayanoglou John | Officer | — | I | Warrants (Right to Buy) | 17,500 | 2.18 | 38.2K | 0 | — | ↗ |
| 2017-06-30 | Ayanoglou John | Officer | — | I | Warrants (Right to Buy) | 7,500 | 2.50 | 18.8K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-58.5K
Shares Outstanding
28.44M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Waqaas Al-Siddiq Chief Executive Officer | 480.0K | 240.0K | — | 522.2K | — | 12.0K | 1.25M | 41.63% | ↗ |
| 2 | 2024 | John Ayanoglou Chief Financial Officer | 300.0K | 250.0K | — | — | — | 12.0K | 562.0K | 0.00% | ↗ |
| 3 | 2023 | Waqaas Al-Siddiq Chief Executive Officer | 480.0K | 240.0K | — | 428.8K | — | 12.0K | 1.16M | 36.94% | ↗ |
| 4 | 2023 | John Ayanoglou Chief Financial Officer | 293.8K | — | — | 232.5K | — | 12.0K | 538.3K | 43.20% | ↗ |
| 5 | 2022 | John Ayanoglou Chief Financial Officer | 300.0K | 75.0K | — | 504.9K | — | 12.0K | 891.9K | 56.61% | ↗ |
| 6 | 2022 | Waqaas Al-Siddiq Chief Executive Officer | 480.0K | 225.0K | — | 169.5K | — | 12.0K | 886.5K | 19.12% | ↗ |
| 7 | 2021 | Waqaas Al-Siddiq Chief Executive Officer | 390.0K | 195.0K | — | 294.3K | — | 12.0K | 891.3K | 33.02% | ↗ |
| 8 | 2021 | John Ayanoglou Chief Financial Officer | 225.0K | — | — | 194.7K | — | 12.0K | 431.7K | 45.10% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Waqaas Al-Siddiq | Founder, President, Chief Executive Officer & Chairman | 732.0K | — |
| S. John Ayanoglou | Chief Financial Officer | 562.0K | male |
| Fareeha Siddiqui | Executive Vice President of Healthcare Solutions | — | — |
| Amir Ali | Chief Development Officer | — | male |
| Spencer LaDow | CISO and Executive VP of Engineering & Regulatory | — | male |
| Matt Zabel | Vice President of Sales & Strategy | — | male |
| Amjad Talpur | Senior Director of Operations | — | — |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BTCY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
